DEFA14A: Beneficient Closes Primary Capital Transaction, Issues Convertible Preferred Stock

Beneficient closed a primary capital transaction, issuing Series B-7 Resettable Convertible Preferred Stock in exchange for a limited partner interest in an investment fund.

Summary

• Beneficient, through a subsidiary, completed a primary capital transaction on April 21, 2025.
• The transaction involved the acquisition of a limited partner interest in an investment fund with a net asset value of $233,333.
• In exchange, the customer received 23,333 shares of Series B-7 Resettable Convertible Preferred Stock.
• This stock is convertible into Class A Common Stock at an initial conversion price of $0.2979 per share, subject to resets and a floor of $0.2234 per share.
• A maximum of 1,044,450 shares of Class A Common Stock may be issued upon conversion.
• The Series B-7 Preferred Stock has optional and mandatory conversion features, with certain limitations based on beneficial ownership and Nasdaq rules.
• Beneficient also entered into a Preferred Liquidity Provider Program Agreement with the Fund to facilitate ongoing liquidity solutions.
• The company believes this transaction will add approximately $77,777 (and an aggregate of approximately $10.54 million) of tangible book value attributable to the company's stockholders upon closing of previously announced Public Stockholder Enhancement Transactions.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting a closed transaction and expected benefits. However, the presence of convertible preferred stock and potential limitations on conversion temper the enthusiasm.

Positives

• The transaction increases the collateral for Beneficient's ExAlt loan portfolio by approximately $233,333.
• The company believes this transaction will add approximately $77,777 (and an aggregate of approximately $10.54 million) of tangible book value attributable to the company's stockholders upon closing of previously announced Public Stockholder Enhancement Transactions.
• The Preferred Liquidity Provider Program Agreement may provide ongoing liquidity solutions for the Fund and its limited partners.

Negatives

• The Series B-7 Preferred Stock conversion is subject to limitations based on beneficial ownership (4.99%) and Nasdaq rules (Exchange Cap), which could delay or restrict conversion.
• The Series B-7 Preferred Stock ranks junior to several other series of preferred stock and all existing and future indebtedness of the company.

Risks

• The conversion of Series B-7 Preferred Stock is subject to beneficial ownership and Exchange Cap limitations.
• The company's forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.
• The ultimate outcome of the Public Stockholder Enhancement Transactions is uncertain, including obtaining the requisite vote of securityholders.

Future Outlook

Beneficient intends to continue pursuing additional opportunities that align with its strategic vision and growth objectives, focusing on primary capital solutions and financing anchor commitments to general partners.

Management Comments

• Beneficient management stated, 'We are excited to continue the momentum at the outset of this fiscal year by completing another GP primary capital transaction as we work to execute on our core liquidity and primary capital strategy.'
• Management also believes that 'this financing reflects our ability to close transactions that drive shareholder value and enhance the value of the collateral backing our ExAlt loan portfolio.'

Industry Context

Beneficient is targeting the underserved market of mid-to-high net worth individuals, small-to-midsized institutions, and General Partners seeking liquidity and capital solutions in the alternative asset investment market.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• More information would be needed about the specific terms of the limited partner interest acquired, the fund's performance, and the terms of similar transactions in the alternative asset market to make a meaningful comparison.
• Without more details, it's difficult to assess whether the terms of this transaction are favorable or unfavorable compared to industry benchmarks.

Stakeholder Impact

• Shareholders may benefit from the potential increase in tangible book value.
• The transaction provides a capital solution for the Cork & Vines Fund I, LP.
• The ExAlt loan portfolio is expected to be enhanced by the increased collateral.

Next Steps

• The company will continue to pursue additional opportunities that align with its strategic vision and growth objectives.
• The company is awaiting the closing of the previously announced Public Stockholder Enhancement Transactions.

Key Dates

Keywords

Series B-7 Preferred Stock, Primary Capital Transaction, Convertible Preferred Stock, Beneficient, AltAccess, Liquidity, Alternative Assets, ExAlt loan portfolio